Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Ainos Inc. (AIMDW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: AIMDW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -97.36% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 2.22 | 52 Weeks Range 0.03 - 0.31 | Updated Date 06/26/2025 |
52 Weeks Range 0.03 - 0.31 | Updated Date 06/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2978.02% |
Management Effectiveness
Return on Assets (TTM) -30.93% | Return on Equity (TTM) -82.87% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 9206027 |
Shares Outstanding - | Shares Floating 9206027 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Ainos Inc.
Company Overview
History and Background
Ainos, Inc., formerly known as Tailong BioTech USA, Inc., was founded in 2004. It initially focused on developing immune-modulatory therapies. The company has evolved through various strategic shifts, including name changes and changes in business focus.
Core Business Areas
- Veterinary Medicine: Ainos offers a range of veterinary medicines for animal health. This includes solutions addressing animal health needs.
- Human Health: Ainos is also involved in the research and development of therapeutic products for human health. It is focused on the development of VELDONA, a low-dose interferon alpha oral tablet for treating certain viral infections.
Leadership and Structure
The leadership team consists of key executives overseeing research and development, operations, and business development. The organizational structure is designed to facilitate the development and commercialization of its products. Steve Chen serves as Chairman and CEO.
Top Products and Market Share
Key Offerings
- VELDONA (low-dose interferon alpha oral tablet): VELDONA is an oral tablet being developed for the treatment of viral infections. As VELDONA is still in development, current market share and revenue figures are not available. Competitors in the antiviral drug space include companies like Pfizer (Paxlovid) and Gilead Sciences (Remdesivir). The number of users is dependent on future FDA approval and market penetration.
- Veterinary Products: Ainos provides veterinary medicines, details on revenue and market share are currently unavailable. Competitors in the animal health market include Zoetis and Elanco.
Market Dynamics
Industry Overview
The pharmaceutical and animal health industries are competitive and highly regulated. Trends include increasing demand for novel therapeutics and growing focus on preventative care.
Positioning
Ainos is positioning itself as an innovator in the antiviral therapeutic space, particularly through oral interferon delivery, as well as an innovative supplier for the Veterinary space.
Total Addressable Market (TAM)
The global antiviral drug market is estimated to be billions of dollars. Ainos Inc. is positioned to capture a portion of this TAM with successful development and commercialization of VELDONA. The animal health market is also in the billions, but Ainos currently has a small position.
Upturn SWOT Analysis
Strengths
- Innovative drug delivery technology (oral interferon)
- Diversified business areas including human and animal health
- Potential for market disruption with VELDONA (if approved)
Weaknesses
- Limited financial resources
- Reliance on successful clinical trials and regulatory approvals
- Limited sales and marketing infrastructure
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Increasing demand for antiviral therapies
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and clinical trial failures
- Patent expirations
Competitors and Market Share
Key Competitors
- PFE
- GILD
- ZTS
- ELAN
Competitive Landscape
Ainos Inc. faces intense competition from established pharmaceutical giants with greater resources and market presence. Its competitive advantage lies in its oral interferon delivery technology and focus on niche therapeutic areas.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been slow and erratic.
Future Projections: Future growth projections are highly dependent on the successful development and commercialization of VELDONA and other products. Analyst estimates are unavailable.
Recent Initiatives: Recent initiatives include ongoing clinical trials for VELDONA and expansion of their veterinary medicine offerings.
Summary
Ainos Inc. is a small company with potential in the antiviral therapeutic space, particularly if its VELDONA product is successful in clinical trials and gains regulatory approval. It is a very weak company with limited financial resources. The company must obtain more funding to sustain operations and clinical trials. Ainos Inc. must also compete with larger, well-established pharmaceutical companies. The company must look out for regulatory hurdles and the need for more funding.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Industry Reports
- Third party analyst reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is approximate and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ainos Inc.
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2022-08-09 | CEO, President & Chairman of the Board Mr. Chun-Hsien Tsai | ||
Sector Healthcare | Industry Medical Devices | Full time employees 44 | Website https://www.ainos.com |
Full time employees 44 | Website https://www.ainos.com | ||
Ainos, Inc., a dual-platform AI and biotech company, focusing SmellTech, AI diagnostics, and immune therapeutics. Its AI Nose platform uses a smell language model to digitize scent into Smell IDs and turning invisible chemical signals into machine-readable data. The company is also giving AI for robotics, smart factories, senior care, and women's health. In addition, it develops VELDONA, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases, plus applications in animal health. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.